Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes

74Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Purpose: Benign epilepsy with centrotemporal spikes (BECTS) is characterized by an excellent prognosis. Drug therapy is necessary in only a minority of patients. Carbamazepine (CBZ) and phenobarbital (PB) have been reported to cause electroclinical aggravation in some cases. The incidence of drug-induced aggravation in BECTS has never been established. Methods: We retrospectively studied 98 consecutive cases of BECTS, examined at the Centre Saint Paul between 1984 and 1999; 82 patients had received one or more treatments, often successively and in association. Results: We found only one case of electroclinical aggravation with CBZ among 40 patients exposed to CBZ (35 in monotherapy, five in polytherapy). An additional case showed a marked EEG aggravation on CBZ + PB among 14 patients taking PB (nine with monotherapy and five with polytherapy), and PB was apparently responsible. No patient treated with valproate or benzodiazepines showed aggravation. Conclusions: Aggravation of BECTS caused by antiepileptic drugs happens only rarely. There is a minor risk of aggravation with CBZ and also probably with PB. Drug-induced aggravation may occur only during certain periods coinciding with spontaneous worsening of BECTS.

Cite

CITATION STYLE

APA

Corda, D., Gelisse, P., Genton, P., Dravet, C., & Baldy-Moulinier, M. (2001). Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia, 42(6), 754–759. https://doi.org/10.1046/j.1528-1157.2001.30000.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free